Rapid Micro Biosystems Announces RMBNucleus™ Mold Alarm for the Growth Direct® System
Rapid Micro Biosystems (Nasdaq: RPID) has launched the RMBNucleus™ Mold Alarm, a new feature for the Growth Direct® System aimed at detecting environmental molds rapidly in pharmaceutical manufacturing. This innovation addresses the critical challenge of slow mold detection, which can jeopardize product safety. The Mold Alarm offers enhanced data integrity and alerts users within 24 hours of detection, allowing for prompt intervention. The product will be available before the end of 2022, and the company is showcasing it at the 2022 PDA Pharmaceutical Microbiology Conference.
- Launch of RMBNucleus™ Mold Alarm enhances product offerings.
- Rapid detection of molds improves product safety and operational efficiency.
- The product will be available on the Growth Direct® System before year-end.
- Continued reliance on manual processes in pharmaceutical monitoring could hinder growth.
- Company has reported significant losses since inception, raising concerns about profitability.
LOWELL, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its newest product, RMBNucleus™ Mold Alarm, which is designed to rapidly detect environmental molds in the pharmaceutical manufacturing process. RMBNucleus™ Mold Alarm is expected to be available on the Growth Direct® System before the end of 2022.
Slow detection and confirmation of mold contamination continues to be a critical challenge within environmental monitoring at pharmaceutical manufacturing facilities and can compromise products, putting patients at risk. RMBNucleus™ Mold Alarm, a new software offering for use on the Growth Direct® System, adds rapid detection allowing for early intervention.
“RMB is committed to supporting life-saving therapies, one patient at a time,” said Rob Spignesi, President and CEO of Rapid Micro Biosystems. “We are excited to introduce RMBNucleus™ Mold Alarm, which will enable our Growth Direct® System to rapidly detect environmental molds in the pharmaceutical manufacturing process. As with each of our products on the Growth Direct® System, RMBNucleus™ Mold Alarm comes with enhanced data integrity and generates automated alerts at the first sign of mold detection in as little as one day, allowing for early intervention and reduced risk of contamination.”
Rapid Micro Biosystems is attending the 2022 PDA Pharmaceutical Microbiology Conference in Washington, D.C. from October 10-12, 2022. The Company will host an exhibit booth including an operational Growth Direct® System to demonstrate its rapid detection technology and the benefits of automation and digitization in the quality control lab.
Investors and other interested parties are invited to register to attend the conference at:
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct® system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct® system brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the timing for the availability of the Company’s RMBNucleus™ Mold Alarm; the effectiveness of the RMBNucleus™ Mold Alarm in the pharmaceutical manufacturing process; and customer interest in and adoption of the RMBNucleus™ Mold Alarm software for the Company's Growth Direct System.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to, the impact of macro-economic volatility and COVID-19 and its variants on the Company’s business and operations, including further delays in placements and validation of new systems; the Company’s significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operating results; the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; risks related to third-parties; its ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks relation to the exploration of strategic alternatives; and the other important factors outlined under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
FAQ
What is the RMBNucleus™ Mold Alarm from Rapid Micro Biosystems (RPID)?
When will the RMBNucleus™ Mold Alarm be available?
What are the benefits of the RMBNucleus™ Mold Alarm?
How does the RMBNucleus™ Mold Alarm impact pharmaceutical manufacturing?
What conference is Rapid Micro Biosystems (RPID) attending to showcase their new product?
